| INTRODUCTION
Pain and discomfort are documented side effects of orthodontic treatment. Almost all patients (95%) report and experience pain or discomfort 1 day after bonding of fixed appliances. 1 In particular, rapid maxillary expansion (RME) is indicated for many different pathological conditions that are clinically manifested by constricted high-arched palate and poor transverse maxillary growth.
2-4 RME is the most effective orthopaedic procedure to increase the maxillary transverse dimension in growing subjects by opening the midpalatal suture. 5 The inflammatory reaction during sutural opening together with the compression of the periodontal ligament may contribute and amplify the pain perception experienced during this kind of treatment. 6 All designs of palatal expanders cause a feeling of constraint and dental soreness due to local inflammation that ultimately results in tooth movement. 7 Pain is dependent upon such factors as age, gender, stress, individual pain threshold, cultural differences, in addition to the amount of force applied. Researchers have already reported that pain associated with orthodontic treatment has a potential impact on daily life, mainly as psychological distress. 8, 9 Orthodontists often suggest to parents to eventually give children, in the first day after visit, drugs for pain that might be caused by the appliances used for orthodontic and orthopaedic treatment. 10 Most of these drugs are nonsteroidal anti-inflammatory drugs (NSAIDs) with analgesic and antipyretic action. 11 Clinicians prescribe these drugs commonly for mild and moderate pains. NSAIDs are the most prescribed analgesic medications, and their efficacy for treating acute pain has been well demonstrated.
11
The peripheral analgesic effect of NSAIDs, such as aspirin, ketoprofen, and ibuprofen, is the result of the inhibition of cyclooxygenase activity. The inhibition suppresses biosynthesis of prostaglandins (Ps) thus preventing the transmission of painful stimuli from peripheral receptors. 12 Ketoprofen lysine salt (KLS) has additional advantages over ketoprofen acid, having a more favourable pharmacokinetics profile, enhanced absorption, and increased gastric tolerability. 13 It is rapidly reabsorbed from the gastrointestinal tract, having a rapid onset of effects. 14 It is more effective than ibuprofen or diclofenac (both NSAIDs) in acute postoperative pain, with safety similar to diclofenac.
Paracetamol/acetaminophen is the most recommended by paediatricians, because it has almost no effect on blood clotting and no detrimental effects on stomach lining. 15 Few studies have reported the association between pain perception and rate of screw activation during RME, [16] [17] [18] but no experimental data are available from the literature on pain relief comparing different analgesic drugs. Therefore, this study was divided into two different research protocols with two main aims:
| MATERIALS AND METHODS

| Study design
In this study, we are comparing the effects of ketoprofen lysine salt vs paracetamol on pain perception in children undergoing RME; it can be divided into two phases (see Figure 1 for the consort diagram):
• The first one is a prospective randomized controlled clinical trial (RCT) in order to understand which one of the two analgesics is the more effective in pain reduction; in this phase, a control group was added.
• During the second one, a prospective case series, the group which reported the best analgesic effect, has been selected and acts as a control group; a new group of patients have been then enrolled and instructed to use the analgesic once a day for the first 3 days of activation. The objective is to test if using an analgesic during the first day, in which the higher pain is usually reported, his effect may reduce significantly pain till the first day of RME activation. 
| RCT-patients
Why this paper is important to paediatric dentists
• Almost all of the children reported at least some discomfort during RME activation; the average pain perception was higher during the first 3 days of activation and it was described as mild to moderate pain.
• This paper provides the first data about pain control during RME with ketoprofen lysine salt and paracetamol/acetaminophen: Ketoprofen lysine salt resulted to be more effective for pain reduction.
• The use of ketoprofen lysine salt once a day for the first 3 days reduced the pain perception during the whole activation of the RME.
development (CS1-CS3 in cervical vertebral maturation), 19 negative posterior transverse discrepancy, 20 the non-concurrent use of analgesics and anti-inflammatory drugs, healthy periodontium. Exclusion criteria included the absence of first maxillary molars, previous RME treatments, periodontal diseases, neurological diseases, and/or genetic diseases. Patients with known hypersensitivity to NSAIDs were excluded.
Informed consent was obtained from parents of all subjects before their recruitment.
All patients agreed and provided written informed consents before entering in the study. The study protocol was approved by the Ethical Committee of the IRCCS Ca' Granda Foundation, Maggiore Hospital, Milan (protocol number: 936).
| RCT-treatment
This first phase included one hundred and sixteen patients (Caucasian ethnicity) with no previous orthodontic treatments, with posterior crossbite and candidate for an RME treatment. Each patient underwent a standardized protocol with RME in the form of Haas palatal expander, bonded through bands on the maxillary first permanent molars.
Patients were randomized into three groups. All the patients of the Group 1 and Group 2 activated the RME for at least seven consecutive days. For pain relief, patients were allowed to take analgesic drugs (ketoprofen 40 mg for Group 1, 40 subjects, or paracetamol 250 mg for Group 2, 40 subjects) during the screw activation. The expansion screw was activated two turns per day (0.5 mm/ d) until the desired expansion was achieved. The expansion was considered complete when the occlusal aspect of the maxillary lingual cusp of upper first molars contacted the occlusal aspect of the vestibular cusp of the mandibular first molars. No specific indication about when to start taking the analgesics was given to parents. All the patients were treated as in everyday clinical practice. No additional pharmacological treatments or supplementary procedures were given.
Group 3 (36 subjects) served as a control group (CTR). In CTR group, patients had their RME bonded with the same clinical protocol as in Group 1 and Group 2 but the screw was not activated for the first week of treatment.
| RCT-outcome measures
Pain assessment was performed using the visual analogue scale (100 mm VAS) associated with a numeric rating scale (0-"no pain," 1-"mild pain," 2-"moderate pain," 3-"strong pain," 4-"unbearable pain") at different time points from the beginning of treatment. 21 Verbal instructions were given to parents and children to correctly assess pain. The patients completed the questionnaire before insertion of the appliance (baseline) and every day for the following days immediately after the activation of the expander. Patients were also asked to report whether they consumed any kind of analgesics drugs each day. The answers were set as a binary choice (yes or no) along with the pain assessment. They located the site of pain or any other discomfort.
| RCT-sample size
Sample size was calculated a priori based on a primary outcome (pain assessment with VAS scale, as continuous outcome) to obtain a statistical power of the study greater than 0.80, using the mean values and standard 
Based on these parameters, to have an 80% chance of detecting as significant (at the two-sided 5% level) a five-point difference between the two groups the sample size required was 39 patients in each study group (Group 1 and Group 2).
| RCT-randomization
One operator created a randomization list with a computer using a dedicated software. A second operator recruited patients and asked to the first one about which analgesic should be given to every single patient. The questionnaires were then analysed by a third operator, who was blinded to the study and did not perform any treatment on the patients.
| Second phase-prospective case series
A fourth group of patients (n.35) have been enrolled after the first phase: Considering the results obtained from the comparison between those who have taken KTS or P, we decided to test if an earlier use of the most effective analgesic might be able to prevent pain during the whole activation of the RME. We evaluated if the intake of a dose of the analgesic once a day for each of the first 3 days of activation may be effective. 
| Statistical analysis
| RESULTS
A total of 151 Caucasian children were enrolled in this study and treated following the daily clinical practice, with oral ketoprofen lysine salt (KLS) at the dose of 40 mg or paracetamol/acetaminophen (P) at the dose of 250 mg. All the patients who reported the use of at least one single dose of pain relief drug and with complete questionnaires have been considered eligible for the statistical evaluations. Rapid maxillary expansion opened the midpalatal suture in all subjects, except in Group 3. Figure 1 reports the diagram for the first phase of the study RCT and the characteristics of the three groups. From the initial sample of eighty subjects (Group 1 and Group 2), eight patients have been excluded due to incomplete questionnaires. Other nine patients have been excluded because they did not use any pain relief drugs.
| RCT-first phase
The Group 1 (KLS) comprised 28 subjects (11 males; 17 females) with a mean age of 8.5 ± 1.8 years; the Group 2 (P) comprised 35 subjects (18 males; 17 females) with a mean age of 8.7 ± 1.8 years. The control group comprised 35 subjects (19 males; 17 females) with a mean age of 8.9 ± 1.2 years.
The average pain perception over time was higher during the first 3 days of activation and it was described as mild to moderate pain (Figure 2) . Patients of the KLS F I G U R E 2 Treatment efficacy evaluated by average level of pain over time in Group 1 (P), Group 2 (KLS), and Group 3(CTR) group reported a single assumption of the drug during the second day of activation. Patients of the P group reported the use of the drug twice during the second and the third day (60%), almost half of the sample (40%) reported the use during only the second day. Only one subject reported drug assumption in the control group and was excluded from the statistical analyses.
Compared with the P, the KLS-treated patients experienced significantly less pain during the fourth, fifth, and sixth day. Compared with control group, subjects in both P and KLS groups experienced significantly more pain during all days (Table 1) .
Ninety-four per cent of the children reported at least some discomfort during RME activation.
During RPE activation, pain was reported to be located more often at the level of anchoring tooth (88.9%), followed by the frontal tooth (33.3%), nose (14.3%), and head (9.5%).
No side effects have been reported.
| Second phase-prospective case series
For the second phase, a new recruitment has been done: Thirty-five more subjects have been enrolled and instructed to take ketoprofen (40 mg) for the first 3 days of active expansion. Four of these have been then excluded due to incomplete questionnaires; thus, the Group 4 (KLS-B) comprised 31 subjects (16 males and 15 females) with a mean age of 8.7 ± 1.6 years. The groups presented no statistically significant differences for gender distribution and for mean age (gender: P = 0.48; mean age: P = 0.69).
The results of the second phase are shown in Figure 3 : Patients that used the KLS once a day for the first 3 days (Group 4) reported almost no pain (higher mean value 0.71) during the whole activation of the RME. The results compared with the control group (Group 2) confirmed a significantly less pain for the first 3 days of activation and a good control of pain even during the other days with no statistical differences and mean values under 0.5 ( Table 2) . 
| DISCUSSION
Maxillary expansion treatments have been used for more than 100 years to correct transverse discrepancy in growing subjects 23 ; however, only few studies have evaluated the discomfort associated with this common clinical procedure. [16] [17] [18] To our knowledge, no studies analysed the outcomes of analgesic drugs on pain relief during active expansion. Therefore, the aim of the present randomized clinical trial was to assess the pain timing and intensity during RME and to compare the effects of ketoprofen lysine salt vs paracetamol/acetaminophen on pain perception. It is already known that ketoprofen lysine salt action has an earlier onset and longer duration but, to the best of our knowledge, this is the first research that evaluates the effect of this drug in orthodontic patients that are treated with RME appliances.
Pain amount, discomfort, and alteration of jaw function are subjective parameters that are normally reported by patients. The VAS and verbal rating scales are normally used to report these data; the validity of these scales has already been confirmed in children who are capable of understanding the concept of hurt and its varying degrees of intensity. 24 The general self-perceived pain revealed low to moderate levels of pain for both treated groups on the second and on the third day. These results are in agreement with those described by Needleman et al 17 and Baldini et al 16 who
assessed the greatest intensity of pain during the first six turns. As in previous studies, 16, 17 we observed that the pain perception steadily decreased in the following days with almost no pain at the end of the first week of active phase. The pain experienced during the early phase of screw activation is probably due to inflammation caused by orthopaedic forces at the level of sutural structures and of anchoring tooth as the palatal soft and periodontal tissues are compressed and stretched. 25 Animal studies have
shown extensive bone and sutural activity with highly vascular disorganized connective tissue of an inflammatory response during active expansion. 26, 27 During the first phase, 17 patients have been excluded due to incomplete questionnaires (n.8) and other nine patients did not use any drugs. In this phase, almost all the patients in the treated groups reported the use of pain relief drugs (88%) and only one in the control group.
KLS group reported the assumption of only one dose during the second day of activation; patients of the P group reported the use of the drug twice during the second and the third day (60%) and during only the second day (40%). Thus, data confirm the longer effect of the ketoprofen compared with paracetamol. Children in the KLS group reported significant lower level of pain during the fourth, fifth, and sixth day of activation ( Table 1) . The different pain perception in the two groups is related to the inhibition of acute inflammatory reaction, characterized by vasodilatation normally observed after orthodontic and orthopaedic adjustments. 10 The main difference between ketoprofen lysine salt and paracetamol/acetaminophen is the mode of action. Paracetamol/acetaminophen does not belong to NSAIDs because it lacks anti-inflammatory properties although their chemical structures are comparable. Whereas NSAIDs block COX-1 and/or COX-2, paracetamol/acetaminophen blocks a third isoform, COX-3, which is expressed only in the brain and the spinal cord. As a consequence, paracetamol's analgesic effect is produced at the central nervous system level and does not act over cell membranes with minimal consequences on decreasing local PGs synthesis. 15, 28 Interestingly almost all the patient evaluated reported the use of a pain relief drug. Otherwise, we believe that not all the patients undergoing RME have the same pain perception, and thus, there are certainly a group of patients that do not need any drugs but we have not a sample to be compared with in this study. Considering this, we have to critically evaluate also the comparison of Group 1 and Group 4: In the fourth group, KLS has been prescribed, and in this sample of patients, there might be some of those that normally do not need analgesic with a possible bias on the analyses of the results obtained. Thus, considering that all the patients of phase 1 reported pain and the need of an analgesic, we believe that the use of pain relief should be always suggested during the first day of RME.
Therefore, the analgesic effect of ketoprofen lysine salt seems to be more effective because as NSAIDs it reduces the production of PGs that enhance the transmission of painful stimuli and increase sensitivity to noxious stimuli such as serotonin, histamine, and bradykinin. 29 T A B L E 2 Descriptive statistics and statistical comparisons of pain level during the first activation week in control group 1 (KLS) and group 4 (KLS-B) | 63
| CONCLUSION
The perceived average level of pain was described as mild or moderate pain with peak during the second and the third day of active expansion. Subjects that took ketoprofen lysine salt experienced lower level of pain during the fourth, fifth, and sixth day of screw activation showing to be more effective than paracetamol/acetaminophen, probably due to the anti-inflammatory properties of the analgesic drug. The use of the analgesic during the first 3 days seems to be even more effective reducing pain till the first day of activation with almost no pain for the whole activation period.
Therefore, the present data suggest that ketoprofen lysine salt, thanks to its peculiar mechanism of action and its efficacy, represents an interesting and valid option in this particular setting.
